PROF

NASDAQ

Profound Medical Corp.

SectorHealth CareIndustryMedical/Dental Instruments

$6.74-0.18 (-2.60%)

News25/Ratings7

Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Price$6.74-0.05 (-0.81%)

04:45 PM06:45 PM

News · 26 weeks50-50%

2025-10-262026-04-19

Mix2390d

SEC Filings13(57%)
Other7(30%)
Earnings2(9%)
Offering1(4%)

Latest news

25 items

7dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
7dPR
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2026 Results Conference Call Details: Date: Thursday, May 7, 2026 Time: 4:30 p.m. ET Live Call Dial-in Numbers: 1-800-717-1738 (North America) or 1-646-307-1865
9dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
9dPR
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "IR Calendar" in the Investors section. About Profound Medical Corp. Pr
22dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
27dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
27dPR
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure™ performed in Dallas Medical Center's state-of-the-art MRI suite. "Having performed hundreds of focal HIFU procedures for prostate cancer patients, we switched to primarily offering the TULSA Procedure because its unique MRI-guidance and thermography allow us to treat a much broader range of prostate diseases, si
41dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
41dPR
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment demonstrates a meaningful and statistically significant improvement over robotic RP in the preservation of erectile function together with continence at 6 months – TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced superiority on the prespecified, primar
44dSEC
Profound Medical Corp. filed SEC Form 8-K: Leadership Update
8-K - Profound Medical Corp. (0001628808) (Filer)
45dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
45dPR
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that the first clinical outcomes from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA Procedure™ with robotic radical prostatectomy in men with localized prostate cancer are scheduled to be presented during the Late-Breaking and High-Impact session at the 41st Annual European Association of Urology ("EAU 2026") Congress in London, UK on March 13, 2026 at 9:40 a.m. EDT
49dSEC
SEC Form 10-K filed by Profound Medical Corp.
10-K - Profound Medical Corp. (0001628808) (Filer)
49dSEC
Profound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
49dPR
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today reported financial results for the fourth quarter and full year ended December 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million. Profound's TULSA-PRO® qualified sales pipe
70dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
70dPR
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2025 Results Conference Call Details: Date: Thursday, March 5, 2026 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI9b6f
70dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
70dPR
Profound Medical Honored with INOVAIT's 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage innovator in interventional MRI ("iMRI") procedures, is pleased to announce that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy (IGT) and artificial intelligence ("AI"). "The Mount Logan Award recognizes an INOVAIT industry member who has consistently exceeded project milestone expectations, reached new heights as a Canadian company, and stood out internationally," said Raphael Ronen, co-executive director of INOVAIT. "Profound Medical has achieved si
77dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
77dPR
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women's Health
TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve® Procedure. The MRI-guided therapy provides women with a non-surgical alternative for treating common gynecologic conditions—delivering targeted relief with no incisions, no blood loss during the procedure, no overnight hospital stay, and a faster recovery. "Sonalleve is giving more women access to a safer, gentler a
86dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
86dPR
Profound Medical Announces Upcoming Investor Events
TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following investor events in February. Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4th-5th in Scottsdale, AZ.BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference: The Company is scheduled to participate in a series of one-on-one meetings February 10th-11th in Snowbir
98dSEC
Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Profound Medical Corp. (0001628808) (Filer)
98dPR
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce the world-renowned Mount Sinai Hospital has successfully treated its first prostate cancer patient with the TULSA-PRO® system. The TULSA Procedure™ represents a major advancement in pr